sur STIMVIA
Stimvia Expands Team to Drive Global Growth of URIS® Therapy
Stimvia, a Czech medical technology firm specializing in non-invasive neuromodulation therapies for overactive bladder, has bolstered its Scientific Advisory Board and commercial leadership. This move supports the global expansion of its flagship URIS® therapy.
The Advisory Board now includes prominent urology experts from the United States, United Kingdom, and Europe. These additions aim to strengthen the company's clinical and scientific leadership and facilitate international market expansion. Notable members include Dr. David R. Staskin from Boston, Prof. Alan J. Wein, Prof. Christopher R. Chapple, and Prof. Bertil Blok.
On the commercial front, Dr. David da Silva and Alim Topdag have joined to lead global distribution and sales efforts. Their experience is expected to aid Stimvia's growth in Europe, LATAM, and beyond, ensuring the international success of URIS®.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de STIMVIA